Antag TherapeuticsTherapeutic peptides for the modulation of GIP biology
Antag Therapeutics is a preclinical stage biotechnology company committed to the development of novel therapeutic peptides for metabolic – and cardiovascular autonomic diseases.
Antag Therapeutics is based on decades of research from the University of Copenhagen focusing on understanding and targeting incretin physiology. Our therapeutic peptides are based on a novel endogenous peptide antagonist discovered by the research teams of Professors Jens Juul Holst and Mette Rosenkilde that has been characterized in several human intervention studies.
Postural orthostatic tachycardia syndrome (POTS)
POTS affects 3 million people in the US, predominantly females of child-bearing age, and is characterized by orthostatic intolerance and tachycardia. Patients have reduced quality of life similar to living with chronic obstructive pulmonary disease and congestive heart failure. Unfortunately, there are no approved medications for POTS, so patients rely on ineffective off-label pharmacological and nonpharmacological treatments.
According to WHO, more than 650 million people worldwide suffer from obesity, and the number increases every year. Obesity leads to comorbidities such as type 2 diabetes, fatty liver disease, stroke, coronary artery disease, cancer and many more. Unfortunately, both dieting, exercise and current pharmacological intervention rarely meet the expectations of physicians and patients.
Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found in the human body. They are designed for once-weekly self-administrable subcutaneous injection
Director at Broadview Ventures Inc
Principal at Novo Holdings
Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors
JULY 15, 2021
Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors.
Novo Seeds invests millions in diabetes venture with huge potential
JUNE 26, 2017
Denmark’s largest business newspaper (Børsen) covers Antag Therapeutic’s launch in this article
Novo Seeds invests millions in new venture
JUNE 26, 2017
MedWatch.dk covers the launch of Antag Therapeutics in the following article in Danish.